Sudeep Pharma IPO Closes Today: Subscription Strong, GMP Slips — Should You Bid?

The ₹895-crore Sudeep Pharma IPO closes for bidding today, after receiving steady interest over the first two days. The offer comprises a ₹95 crore fresh issue and an ₹800 crore offer for sale.

The price band is ₹563–₹593 per share, and retail investors must apply for a minimum of ₹14,825.

So far, the IPO has been subscribed 5.13 times, driven largely by non-institutional investors.

Advertisement

• Retail subscription: 5.02x

• NII subscription: Strong

• QIB subscription: 0.13x (muted)

The share allotment will be finalised on November 26, followed by listing on the NSE and BSE on November 28.

Should You Subscribe?

Brokerages hold a mostly positive medium- to long-term outlook, though opinions vary on valuation.

Growth Tailwinds

Master Capital Services said Sudeep Pharma benefits from strong sector demand in:

• Food and nutrition ingredients (India’s market projected to grow from $22 billion in 2024 to $32 billion by 2029)

• Vitamins and minerals, which are expected to see substantial expansion

The brokerage highlighted the company’s diversified portfolio and technology-led manufacturing as key strengths.

Valuation Concerns

Geojit Investments noted that while Sudeep Pharma is “well-positioned for sustained long-term growth,” the IPO is not cheap.
At the upper band of ₹593, it is valued at a P/E of 48, which the brokerage considers fair but demanding.

Even so, Geojit issued a “Subscribe” rating for medium- and long-term investors, citing the company’s financial strength and expansion into battery-grade minerals.

Grey Market Premium (GMP)

The GMP has cooled from its earlier peak of ₹130 to ₹86 today.
This indicates an estimated listing price of around ₹679, roughly 14.5% above the upper price band.

Analysts say this suggests moderate listing gains, but nothing guaranteed.

Who Should Apply?

The IPO offers:

• Solid sector tailwinds

• Strong financials

• Expansion-driven growth outlook

But valuation may feel expensive for short-term investors. Experts believe the issue is more suitable for long-term investors than those seeking quick listing gains.